LAPIX Therapeutics Announces Positive Results from Phase 1 Trial of LPX-TI641

LAPIX Therapeutics Announces Positive Results from Phase 1 Trial of LPX-TI641

By, Admin 23 November 2024

LAPIX Therapeutics announces positive results from phase 1 trial of LPX-TI641 for autoimmune diseases treatment

Overview

LAPIX Therapeutics, Inc. (LAPIX), a clinical-stage biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases, announced positive topline results from its phase I randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of LPX-TI641 after oral dosing in healthy adult volunteers, LPX641-101 (NCT05853835).

The Outcomes: Phase 1 Clinical Trial

  • The phase 1 clinical trial results showed LPX-TI641 to be safe and well tolerated over the course of the tested oral doses from 10 mg to 150 mg in the SAD, and 30 mg to 120 mg once daily oral doses for up to 7 days in the MAD portion of the trial. 
  • A maximum tolerated dose was not identified in this trial. 
  • Adverse events were primarily mild and were sporadically observed across both placebo and treatment groups and not linked to dosage levels. 
  • Mild headaches were the most reported adverse event. 
  • Notably, treatment-emergent neutropenia and lymphocytopenia - two of the most common side effects associated with autoimmune therapies - were absent in subjects administered various doses of LPX-TI641.

Words from the CEO: LAPIX

  • We are committed to innovating around the complexities of the immune system,” said Anas M. Fathallah, Ph.D., co-founder and CEO of LAPIX. 
  • The emerging preliminary data, particularly the observed exposure dependent changes in our key exploratory biomarkers, T-regs and B-regs, highlight LPX-TI641’s potential as a leading therapy for autoimmune disease. We are eager to advance this promising candidate into a phase Ib study in RA and PsA and create a potential new oral standard of care for patients battling autoimmune diseases.

LPX-TI641 Effects 

  • LPX-TI641 demonstrated oral bioavailability with a dose-dependent increase in exposure at higher doses. 
  • Preliminary exploratory pharmacodynamic data from the study revealed an LPX-TI641 exposure dependent and statistically significant increase in circulating CD4+/Foxp3+ T-cells (T-regs) and CD25+/CD19+ B-cells (B-regs) compared to pooled placebo group.

The Phase I Clinical Trial

  • The phase I clinical trial utilized six SAD and three MAD cohorts. 
  • A total of 72 subjects (eight subjects per cohort, six on active treatment and two on placebo) were enrolled consecutively in the study. 
  • Out of the 72 subjects, 70 completed all scheduled study activities and visits. 
  • Two subjects withdrew from the study for personal reasons conflicting with study activities, unrelated to drug adverse effects.

About LPX-TI641

  • LPX-TI641 is an oral, small-molecule designed to bind the phosphatidylserine binding pocket on the T cell/transmembrane, immunoglobulin, and mucin (Tim) family of receptors. 
  • It is currently under clinical development for autoimmune indications such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and multiple sclerosis with plans to expand to other autoimmune indications where the underlying pathology involves immune imbalances and loss of self-tolerance.
  • LPX-TI641’s primary pharmacology works to restore the adaptive immune system’s self-tolerance rather than suppressing immunity, enabling patients to more effectively and gently combat autoimmune disease.
  • oxicological studies and emerging clinical data show that LPX-TI641 does not induce neutropenia or lymphocytopenia, suggesting a potentially improved safety profile compared to current therapies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!